The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study
Background and purpose Uncertainty remains regarding the impact of enteric-coated aspirin (EC-ASA) on secondary prevention of ischemic stroke compared to plain aspirin (P-ASA). Hence, this study was designed to investigate the effect of EC formulation on ASA response via evaluating thromboxane B2 (T...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 2022-11, Vol.78 (11), p.1801-1811 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1811 |
|---|---|
| container_issue | 11 |
| container_start_page | 1801 |
| container_title | European journal of clinical pharmacology |
| container_volume | 78 |
| creator | Elshafei, Mohamed Nabil Imam, Yahia Alsaud, Arwa Ebrahim Chandra, Prem Parray, Aijaz Abdelmoneim, Mohamed S. Obeidat, Khaldun Saeid, Razan Ali, Mohammad Ayadathil, Raheem Mohamed, Mouhand F. H. Abdallah, Ibtihal M. Mohammed, Shaban Akhtar, Naveed Danjuma, Mohammed Ibn-Masoud |
| description | Background and purpose
Uncertainty remains regarding the impact of enteric-coated aspirin (EC-ASA) on secondary prevention of ischemic stroke compared to plain aspirin (P-ASA). Hence, this study was designed to investigate the effect of EC formulation on ASA response via evaluating thromboxane B2 (TXB2) levels in patients with suspected or newly diagnosed stroke.
Methods
A prospective cohort study on suspected or newly diagnosed ischemic stroke patients who are aspirin-naive was conducted. Patients were received either EC aspirin or plain aspirin for at least 3 days. The primary outcome was the proportion of aspirin non-responsiveness between two groups (level of residual serum TXB2 associated with elevated thrombotic risk ( 3.1 ng/ml) within 72 h after three daily aspirin doses, while secondary outcomes were the incidence of early gastrointestinal tract (GIT) bleeding with the various aspirin preparations. (Trial registration: Clinicaltrials.gov NCT04330872 registered on 02 April 2020).
Results
Of 42 patients, ischemic strokes were confirmed in both P-ASA (81%) and EC-ASA (67%) arms. ASA non-responsiveness showed no significant difference between the two formulations (P-ASA vs. EC-ASA; 28.6% vs 23.8%;
P
= 0.726). Univariate and multivariate logistic regression analysis showed that patients treated with EC-ASA were more likely to have a lower rate of non-responders compared to P-ASA (unadjusted OR 0.78; 95% CI 0.20, 3.11); with the risk highest in type 2 diabetic patients with HBA1c > 6.5% (adjusted OR 6; 95% CI 1.02, 35.27;
P
= 0.047). No incidence of GIT bleeding observed throughout the study.
Conclusion
A significant proportion of ASA non-responsiveness was recorded regardless of ASA formulation administered. The increased risk of ASA non-responsiveness in diabetic patients needs further exploration by larger prospective studies. |
| doi_str_mv | 10.1007/s00228-022-03391-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9546947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2722605906</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-f3cf397b5940338673abeba3850ed37281ea2ad4bf6adb8fc1ef7d9782e75e0c3</originalsourceid><addsrcrecordid>eNp9ks1u1DAQxyMEokvhBThZ4lIOKf5I4rgHpGpVaKVKHFrOluNMNi6JHeyk1T4bL8dsUxXBgYttzfzmPx-eLHvP6CmjVH5KlHJe53jkVAjFcv4i27BC8JzRgr3MNpQKlldK0qPsTUp3lLJSUfE6OxIV46xQapP9uu2BuHEydiahI-BniM4SG8zs_O5gMmly0XkS_PMzQpqCT-4ePKRE0DIhjrGJPLi5J2lJE9gZWhIi8fAw7EnrzM6HhCaXbA8j5khzDD_gjEwxPOIoh3n7EGd0Le3-7JBnGVC0i2EkMxZ6crE9v7m6-bgCb7NXnRkSvHu6j7PvXy5ut5f59bevV9vz69wWJZvzTthOKNmUqsAx1ZUUpoHGiLqk0ArJawaGm7Zousq0Td1ZBp1slaw5yBKoFcfZ51V3WpoRWouNRjPoKbrRxL0Oxum_Pd71ehfutSqLShUSBU6eBGL4uUCa9YhTgGEwHsKSNJeslIoWokL0wz_oXViix_aQ4ryi-IMHiq-UxdmlCN1zMYzqw27odTc0HvpxNzTHILEGJYT9DuIf6f9E_Qb4H8B9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2722605906</pqid></control><display><type>article</type><title>The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study</title><source>Springer Nature - Complete Springer Journals</source><creator>Elshafei, Mohamed Nabil ; Imam, Yahia ; Alsaud, Arwa Ebrahim ; Chandra, Prem ; Parray, Aijaz ; Abdelmoneim, Mohamed S. ; Obeidat, Khaldun ; Saeid, Razan ; Ali, Mohammad ; Ayadathil, Raheem ; Mohamed, Mouhand F. H. ; Abdallah, Ibtihal M. ; Mohammed, Shaban ; Akhtar, Naveed ; Danjuma, Mohammed Ibn-Masoud</creator><creatorcontrib>Elshafei, Mohamed Nabil ; Imam, Yahia ; Alsaud, Arwa Ebrahim ; Chandra, Prem ; Parray, Aijaz ; Abdelmoneim, Mohamed S. ; Obeidat, Khaldun ; Saeid, Razan ; Ali, Mohammad ; Ayadathil, Raheem ; Mohamed, Mouhand F. H. ; Abdallah, Ibtihal M. ; Mohammed, Shaban ; Akhtar, Naveed ; Danjuma, Mohammed Ibn-Masoud</creatorcontrib><description>Background and purpose
Uncertainty remains regarding the impact of enteric-coated aspirin (EC-ASA) on secondary prevention of ischemic stroke compared to plain aspirin (P-ASA). Hence, this study was designed to investigate the effect of EC formulation on ASA response via evaluating thromboxane B2 (TXB2) levels in patients with suspected or newly diagnosed stroke.
Methods
A prospective cohort study on suspected or newly diagnosed ischemic stroke patients who are aspirin-naive was conducted. Patients were received either EC aspirin or plain aspirin for at least 3 days. The primary outcome was the proportion of aspirin non-responsiveness between two groups (level of residual serum TXB2 associated with elevated thrombotic risk (< 99.0% inhibition or TXB2 > 3.1 ng/ml) within 72 h after three daily aspirin doses, while secondary outcomes were the incidence of early gastrointestinal tract (GIT) bleeding with the various aspirin preparations. (Trial registration: Clinicaltrials.gov NCT04330872 registered on 02 April 2020).
Results
Of 42 patients, ischemic strokes were confirmed in both P-ASA (81%) and EC-ASA (67%) arms. ASA non-responsiveness showed no significant difference between the two formulations (P-ASA vs. EC-ASA; 28.6% vs 23.8%;
P
= 0.726). Univariate and multivariate logistic regression analysis showed that patients treated with EC-ASA were more likely to have a lower rate of non-responders compared to P-ASA (unadjusted OR 0.78; 95% CI 0.20, 3.11); with the risk highest in type 2 diabetic patients with HBA1c > 6.5% (adjusted OR 6; 95% CI 1.02, 35.27;
P
= 0.047). No incidence of GIT bleeding observed throughout the study.
Conclusion
A significant proportion of ASA non-responsiveness was recorded regardless of ASA formulation administered. The increased risk of ASA non-responsiveness in diabetic patients needs further exploration by larger prospective studies.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-022-03391-2</identifier><identifier>PMID: 36121499</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aspirin ; Biomedical and Life Sciences ; Biomedicine ; Bleeding ; Clinical Trial ; Cohort analysis ; Diabetes ; Diabetes mellitus ; Gastrointestinal tract ; Ischemia ; Pharmacology/Toxicology ; Stroke</subject><ispartof>European journal of clinical pharmacology, 2022-11, Vol.78 (11), p.1801-1811</ispartof><rights>The Author(s) 2022</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-f3cf397b5940338673abeba3850ed37281ea2ad4bf6adb8fc1ef7d9782e75e0c3</citedby><cites>FETCH-LOGICAL-c451t-f3cf397b5940338673abeba3850ed37281ea2ad4bf6adb8fc1ef7d9782e75e0c3</cites><orcidid>0000-0002-3229-6825</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00228-022-03391-2$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00228-022-03391-2$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Elshafei, Mohamed Nabil</creatorcontrib><creatorcontrib>Imam, Yahia</creatorcontrib><creatorcontrib>Alsaud, Arwa Ebrahim</creatorcontrib><creatorcontrib>Chandra, Prem</creatorcontrib><creatorcontrib>Parray, Aijaz</creatorcontrib><creatorcontrib>Abdelmoneim, Mohamed S.</creatorcontrib><creatorcontrib>Obeidat, Khaldun</creatorcontrib><creatorcontrib>Saeid, Razan</creatorcontrib><creatorcontrib>Ali, Mohammad</creatorcontrib><creatorcontrib>Ayadathil, Raheem</creatorcontrib><creatorcontrib>Mohamed, Mouhand F. H.</creatorcontrib><creatorcontrib>Abdallah, Ibtihal M.</creatorcontrib><creatorcontrib>Mohammed, Shaban</creatorcontrib><creatorcontrib>Akhtar, Naveed</creatorcontrib><creatorcontrib>Danjuma, Mohammed Ibn-Masoud</creatorcontrib><title>The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>Background and purpose
Uncertainty remains regarding the impact of enteric-coated aspirin (EC-ASA) on secondary prevention of ischemic stroke compared to plain aspirin (P-ASA). Hence, this study was designed to investigate the effect of EC formulation on ASA response via evaluating thromboxane B2 (TXB2) levels in patients with suspected or newly diagnosed stroke.
Methods
A prospective cohort study on suspected or newly diagnosed ischemic stroke patients who are aspirin-naive was conducted. Patients were received either EC aspirin or plain aspirin for at least 3 days. The primary outcome was the proportion of aspirin non-responsiveness between two groups (level of residual serum TXB2 associated with elevated thrombotic risk (< 99.0% inhibition or TXB2 > 3.1 ng/ml) within 72 h after three daily aspirin doses, while secondary outcomes were the incidence of early gastrointestinal tract (GIT) bleeding with the various aspirin preparations. (Trial registration: Clinicaltrials.gov NCT04330872 registered on 02 April 2020).
Results
Of 42 patients, ischemic strokes were confirmed in both P-ASA (81%) and EC-ASA (67%) arms. ASA non-responsiveness showed no significant difference between the two formulations (P-ASA vs. EC-ASA; 28.6% vs 23.8%;
P
= 0.726). Univariate and multivariate logistic regression analysis showed that patients treated with EC-ASA were more likely to have a lower rate of non-responders compared to P-ASA (unadjusted OR 0.78; 95% CI 0.20, 3.11); with the risk highest in type 2 diabetic patients with HBA1c > 6.5% (adjusted OR 6; 95% CI 1.02, 35.27;
P
= 0.047). No incidence of GIT bleeding observed throughout the study.
Conclusion
A significant proportion of ASA non-responsiveness was recorded regardless of ASA formulation administered. The increased risk of ASA non-responsiveness in diabetic patients needs further exploration by larger prospective studies.</description><subject>Aspirin</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bleeding</subject><subject>Clinical Trial</subject><subject>Cohort analysis</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Gastrointestinal tract</subject><subject>Ischemia</subject><subject>Pharmacology/Toxicology</subject><subject>Stroke</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp9ks1u1DAQxyMEokvhBThZ4lIOKf5I4rgHpGpVaKVKHFrOluNMNi6JHeyk1T4bL8dsUxXBgYttzfzmPx-eLHvP6CmjVH5KlHJe53jkVAjFcv4i27BC8JzRgr3MNpQKlldK0qPsTUp3lLJSUfE6OxIV46xQapP9uu2BuHEydiahI-BniM4SG8zs_O5gMmly0XkS_PMzQpqCT-4ePKRE0DIhjrGJPLi5J2lJE9gZWhIi8fAw7EnrzM6HhCaXbA8j5khzDD_gjEwxPOIoh3n7EGd0Le3-7JBnGVC0i2EkMxZ6crE9v7m6-bgCb7NXnRkSvHu6j7PvXy5ut5f59bevV9vz69wWJZvzTthOKNmUqsAx1ZUUpoHGiLqk0ArJawaGm7Zousq0Td1ZBp1slaw5yBKoFcfZ51V3WpoRWouNRjPoKbrRxL0Oxum_Pd71ehfutSqLShUSBU6eBGL4uUCa9YhTgGEwHsKSNJeslIoWokL0wz_oXViix_aQ4ryi-IMHiq-UxdmlCN1zMYzqw27odTc0HvpxNzTHILEGJYT9DuIf6f9E_Qb4H8B9</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Elshafei, Mohamed Nabil</creator><creator>Imam, Yahia</creator><creator>Alsaud, Arwa Ebrahim</creator><creator>Chandra, Prem</creator><creator>Parray, Aijaz</creator><creator>Abdelmoneim, Mohamed S.</creator><creator>Obeidat, Khaldun</creator><creator>Saeid, Razan</creator><creator>Ali, Mohammad</creator><creator>Ayadathil, Raheem</creator><creator>Mohamed, Mouhand F. H.</creator><creator>Abdallah, Ibtihal M.</creator><creator>Mohammed, Shaban</creator><creator>Akhtar, Naveed</creator><creator>Danjuma, Mohammed Ibn-Masoud</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3229-6825</orcidid></search><sort><creationdate>20221101</creationdate><title>The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study</title><author>Elshafei, Mohamed Nabil ; Imam, Yahia ; Alsaud, Arwa Ebrahim ; Chandra, Prem ; Parray, Aijaz ; Abdelmoneim, Mohamed S. ; Obeidat, Khaldun ; Saeid, Razan ; Ali, Mohammad ; Ayadathil, Raheem ; Mohamed, Mouhand F. H. ; Abdallah, Ibtihal M. ; Mohammed, Shaban ; Akhtar, Naveed ; Danjuma, Mohammed Ibn-Masoud</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-f3cf397b5940338673abeba3850ed37281ea2ad4bf6adb8fc1ef7d9782e75e0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aspirin</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bleeding</topic><topic>Clinical Trial</topic><topic>Cohort analysis</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Gastrointestinal tract</topic><topic>Ischemia</topic><topic>Pharmacology/Toxicology</topic><topic>Stroke</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elshafei, Mohamed Nabil</creatorcontrib><creatorcontrib>Imam, Yahia</creatorcontrib><creatorcontrib>Alsaud, Arwa Ebrahim</creatorcontrib><creatorcontrib>Chandra, Prem</creatorcontrib><creatorcontrib>Parray, Aijaz</creatorcontrib><creatorcontrib>Abdelmoneim, Mohamed S.</creatorcontrib><creatorcontrib>Obeidat, Khaldun</creatorcontrib><creatorcontrib>Saeid, Razan</creatorcontrib><creatorcontrib>Ali, Mohammad</creatorcontrib><creatorcontrib>Ayadathil, Raheem</creatorcontrib><creatorcontrib>Mohamed, Mouhand F. H.</creatorcontrib><creatorcontrib>Abdallah, Ibtihal M.</creatorcontrib><creatorcontrib>Mohammed, Shaban</creatorcontrib><creatorcontrib>Akhtar, Naveed</creatorcontrib><creatorcontrib>Danjuma, Mohammed Ibn-Masoud</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elshafei, Mohamed Nabil</au><au>Imam, Yahia</au><au>Alsaud, Arwa Ebrahim</au><au>Chandra, Prem</au><au>Parray, Aijaz</au><au>Abdelmoneim, Mohamed S.</au><au>Obeidat, Khaldun</au><au>Saeid, Razan</au><au>Ali, Mohammad</au><au>Ayadathil, Raheem</au><au>Mohamed, Mouhand F. H.</au><au>Abdallah, Ibtihal M.</au><au>Mohammed, Shaban</au><au>Akhtar, Naveed</au><au>Danjuma, Mohammed Ibn-Masoud</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study</atitle><jtitle>European journal of clinical pharmacology</jtitle><stitle>Eur J Clin Pharmacol</stitle><date>2022-11-01</date><risdate>2022</risdate><volume>78</volume><issue>11</issue><spage>1801</spage><epage>1811</epage><pages>1801-1811</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Background and purpose
Uncertainty remains regarding the impact of enteric-coated aspirin (EC-ASA) on secondary prevention of ischemic stroke compared to plain aspirin (P-ASA). Hence, this study was designed to investigate the effect of EC formulation on ASA response via evaluating thromboxane B2 (TXB2) levels in patients with suspected or newly diagnosed stroke.
Methods
A prospective cohort study on suspected or newly diagnosed ischemic stroke patients who are aspirin-naive was conducted. Patients were received either EC aspirin or plain aspirin for at least 3 days. The primary outcome was the proportion of aspirin non-responsiveness between two groups (level of residual serum TXB2 associated with elevated thrombotic risk (< 99.0% inhibition or TXB2 > 3.1 ng/ml) within 72 h after three daily aspirin doses, while secondary outcomes were the incidence of early gastrointestinal tract (GIT) bleeding with the various aspirin preparations. (Trial registration: Clinicaltrials.gov NCT04330872 registered on 02 April 2020).
Results
Of 42 patients, ischemic strokes were confirmed in both P-ASA (81%) and EC-ASA (67%) arms. ASA non-responsiveness showed no significant difference between the two formulations (P-ASA vs. EC-ASA; 28.6% vs 23.8%;
P
= 0.726). Univariate and multivariate logistic regression analysis showed that patients treated with EC-ASA were more likely to have a lower rate of non-responders compared to P-ASA (unadjusted OR 0.78; 95% CI 0.20, 3.11); with the risk highest in type 2 diabetic patients with HBA1c > 6.5% (adjusted OR 6; 95% CI 1.02, 35.27;
P
= 0.047). No incidence of GIT bleeding observed throughout the study.
Conclusion
A significant proportion of ASA non-responsiveness was recorded regardless of ASA formulation administered. The increased risk of ASA non-responsiveness in diabetic patients needs further exploration by larger prospective studies.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>36121499</pmid><doi>10.1007/s00228-022-03391-2</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-3229-6825</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 2022-11, Vol.78 (11), p.1801-1811 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9546947 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Aspirin Biomedical and Life Sciences Biomedicine Bleeding Clinical Trial Cohort analysis Diabetes Diabetes mellitus Gastrointestinal tract Ischemia Pharmacology/Toxicology Stroke |
| title | The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T18%3A49%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20enteric%20coating%20of%20aspirin%20on%20aspirin%20responsiveness%20in%20patients%20with%20suspected%20or%20newly%20diagnosed%20ischemic%20stroke:%20prospective%20cohort%20study:%20results%20from%20the%20(ECASIS)%20study&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Elshafei,%20Mohamed%20Nabil&rft.date=2022-11-01&rft.volume=78&rft.issue=11&rft.spage=1801&rft.epage=1811&rft.pages=1801-1811&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-022-03391-2&rft_dat=%3Cproquest_pubme%3E2722605906%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2722605906&rft_id=info:pmid/36121499&rfr_iscdi=true |